Gossamer Bio, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
GOSS$11.28+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three months ended September 30, | Nine months ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue: | ||||
| Revenue from contracts with collaborators | $38,431 | $13,294 | $64,624 | $34,672 |
| Total revenue | 38,431 | 13,294 | 64,624 | 34,672 |
| Operating expenses: | ||||
| Research and development | 18,828 | 45,542 | 88,315 | 125,158 |
| In process research and development | 2,771 | 7,476 | 2,771 | 7,476 |
| General and administrative | 9,637 | 9,390 | 37,283 | 26,727 |
| Total operating expenses | 31,236 | 62,408 | 128,369 | 159,361 |
| Income (Loss) from operations | 7,195 | (49,114) | (63,745) | (124,689) |
| Other income (expense) | ||||
| Interest income | 400 | 687 | 1,022 | 1,523 |
| Interest expense | (2,464) | (2,748) | (7,924) | (8,238) |
| Remeasurement of warrant liability | (56,531) | — | (54,929) | — |
| Remeasurement of derivative liability | 5,569 | — | 9,682 | — |
| Gain on debt extinguishment | — | — | 43,846 | — |
| Other income (loss), net | (2,241) | 2,954 | (5,788) | 8,272 |
| Total other income (expense), net | (55,267) | 893 | (14,091) | 1,557 |
| Net (loss) | $(48,072) | $(48,221) | $(77,836) | $(123,132) |
| Other comprehensive income (loss): | ||||
| Foreign currency translation | 119 | (130) | 1,602 | (6,228) |
| Unrealized gain (loss) on marketable securities | — | 111 | (68) | (68) |
| Other comprehensive income (loss) | 119 | (19) | 1,534 | (6,296) |
| Comprehensive (loss) | $(47,953) | $(48,240) | $(76,302) | $(129,428) |
| Net loss per share, basic | $(7.36) | $(16.92) | $(17.30) | $(43.33) |
| Net loss per share, diluted | $(7.36) | $(16.92) | $(25.61) | $(43.33) |
| Weighted average common shares outstanding, basic | 6,530,004 | 2,849,768 | 4,498,832 | 2,842,032 |
| Weighted average common shares outstanding, diluted | 6,530,004 | 2,849,768 | 4,586,281 | 2,842,032 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.